A prostate cancer drug has been rejected for use on the NHS, as experts condemned the “ disappointing ” decision that will deny patients access to the “ revolutionary ” treatment. Clinical trials have shown that people taking olaparib( also called Lynparza) have more time before their disease gets worse and live longer overall compared to other treatments. Scientists have called on NHS England to be more “ flexible ” when it comes to approving innovative treatments. More than 47, 500 men are dia